Biotech Catalysts This Week: 1 Trial Completion and 10 New Financings (Oct 4-11, 2026)
This week’s calendar is light on regulatory action, with no FDA decisions due and the sole trial primary completion date falling to BMY’s ADEPT-1 study of KarXT in Alzheimer’s-associated psychosis. Activity instead clusters around forward guidance, with eight companies including GLUE, MBRX, DYN, and MIRM issuing new timelines stretching into 2026 and 2027, alongside 10 new financing filings and two trial status changes at ARVN and CORT.
At a glance: this week no FDA decision dates, 1 Phase 2 or 3 trial reaching primary completion and 10 new financing filings. Last week: 8 new timelines announced.
🔄 What Changed Last Week
New timelines announced in press releases:
- GLUE, MRT-8102: H2 2027. “Initial data are expected in H2 2027.” SEC filing
- MBRX, MBRX: first quarter of 2027. “With enrollment closed at 89 subjects, or potentially more, the Company remains on track for its planned comprehensive data readout of Part A in the first quarter of 2027.” SEC filing
- DYN, ACHIEVE REC: Q1 2027. “The change from baseline in vHOT at 6 months is the primary endpoint of the ACHIEVE REC, from which topline data are expected in Q1 2027 to support a potential Biologics License…” SEC filing
- IVA, NATiV3: fourth quarter of 2026. “Topline results of the Phase 3 NATiV3 clinical trial are expected in the fourth quarter of 2026” SEC filing
- MIRM, AZURE-2 and AZURE-3: second half of 2027. “Topline results from the Phase 3 AZURE-2 and AZURE-3 studies are expected in the second half of 2027.” SEC filing
- CGEM, RTOR: by year-end 2026. “Completion of the NDA submission is expected by year-end 2026.” SEC filing
- GANX, rexaceract: first quarter of 2027. “The Company expects to submit a new Phase 2 study protocol to the U.S. Food and Drug Administration (the “FDA”) in the coming weeks, informed by insights provided by the Phase 1b…” SEC filing
- AGMB, NOV-ERA: coming months. “Next steps with ontunisertib: NOV-ERA Phase 2b study Agomab recently completed regulatory filings for NOV-ERA, a global Phase 2b trial designed to evaluate ontunisertib in…” SEC filing
Trial status changes on ClinicalTrials.gov:
- ARVN: Phase 1, Phase 2 trial marked completed (2026-10-03). TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines Registry
- CORT: Phase 2 trial marked completed (2026-09-28). A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabo Registry
🧪 Phase 2 and 3 Trials Reaching Primary Completion
Estimated primary completion dates from ClinicalTrials.gov: the last patient reaches the main endpoint. Topline results usually follow weeks or months later.
- BMY, 2026-10-05 (Phase 3): A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer’s Disease (ADEPT-1) Registry
📡 Run-up Radar Highlights
Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):
- ZURA: Phase 2 primary completion in 28 days, score 61/100
- VSTM: Data readout guided for October 2026, window closes in 27 days, score 61/100
- SLDB: Phase 1/2 primary completion in 11 days, score 54/100
💸 Dilution Watch: New Financing Filings
- SILO: private placement (8-K, 2026-10-02) EDGAR
- MGRX: private placement (8-K, 2026-10-01) EDGAR
- BSEM: private placement (8-K, 2026-09-30) EDGAR
- BYSI: ATM program up to $12M (424B5, 2026-09-29) EDGAR
- IMNN: private placement (8-K, 2026-09-29) EDGAR
- SMMT: private placement (8-K, 2026-09-29) EDGAR
- LXEO: private placement (8-K, 2026-09-29) EDGAR
- CELU: private placement (8-K, 2026-09-28) EDGAR
- ADRX: registered direct offering $446M (424B4, 2026-09-28) EDGAR
- ADRX: private placement (8-K, 2026-09-28) EDGAR
📈 Last Week’s Biggest Gainers
- IOVA +31.48% (volume 4.7x average)
- UTHR +12.55% (volume 6.0x average)
- IBRX +10.83% (volume 3.1x average)
- SLS +6.95% (volume 1.2x average)
- PGEN +6.34% (volume 2.4x average)
Earlier weekly catalyst recaps →
Track your tickers on the BioRadar dashboard →
This digest is for informational purposes only and is not investment advice. Always do your own research.